Intervention Review

Alemtuzumab for patients with chronic lymphocytic leukaemia

  1. Nicole Skoetz1,*,
  2. Kathrin Bauer1,
  3. Thomas Elter2,
  4. Ina Monsef1,
  5. Verena Roloff3,
  6. Michael Hallek2,
  7. Andreas Engert1

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 15 FEB 2012

Assessed as up-to-date: 21 NOV 2011

DOI: 10.1002/14651858.CD008078.pub2

How to Cite

Skoetz N, Bauer K, Elter T, Monsef I, Roloff V, Hallek M, Engert A. Alemtuzumab for patients with chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2012, Issue 2. Art. No.: CD008078. DOI: 10.1002/14651858.CD008078.pub2.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    University Hospital of Cologne, Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, Cologne, Germany

  3. 3

    MRC Biostatistics Unit, Cambridge, UK

*Nicole Skoetz, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. nicole.skoetz@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 15 FEB 2012

SEARCH

  1. Current Version

    Alemtuzumab for patients with chronic lymphocytic leukaemia

    Nicole Skoetz, Kathrin Bauer, Thomas Elter, Ina Monsef, Verena Roloff, Michael Hallek and Andreas Engert

    Article first published online: 15 FEB 2012 | DOI: 10.1002/14651858.CD008078.pub2

Previous versions of this article and their online publication dates

  1. Version 1

    Alemtuzumab for chronic lymphocytic leukaemia

    Thomas Elter, Olaf Weingart, Kathrin Bauer, Corinne Brillant, Christine Herbst, Ina Monsef, Nicole Skoetz and Andreas Engert

    Article first published online: 7 OCT 2009 | DOI: 10.1002/14651858.CD008078